BigMove Ventures announced on the 30th that it has invested in VPix Medical, a startup that operates a digital biopsy diagnostic platform.
Founded in 2016, VPix Medical is a biotech company that developed "cCell," a digital biopsy platform capable of real-time biopsies during surgery. With this investment, the company plans to actively expand its clinical trials and establish a global distribution network.
Jung Hoon-jae, CEO of Big Move Ventures, said, “VPix Medical’s cCell platform is an innovative technology that can perform biopsies in real time during surgery, and its technological prowess has been proven through domestic New Excellent Technology (NET) certification and U.S. Food and Drug Administration (FDA) approval.” He added, “We decided to invest considering its excellent competitiveness and growth potential.”
Big Move Ventures is expanding its investment portfolio, focusing on the biohealthcare sector. Recent investments include Impact AI, operator of "ADoasis," an AI-based advertising budget optimization solution; Connective, a developer of AI-based musculoskeletal surgery support solutions and surgical robots; Cham Yaksa, a pharmacy digital transformation platform; Innoclas, a genome analysis company; and Sum Air, a small aircraft operator startup. The firm is strengthening its position as an investment firm encompassing both biohealthcare and ESG.
A Big Move Ventures representative stated, “Having recently been selected for a major investment project, we are focusing on discovering and supporting companies with high growth potential along with sound investments.”
- See more related articles
You must be logged in to post a comment.